IL2 and neuroblastoma: Comparative analyses indicated that infusions of DB (in combination with 13-cis-retinoic acid and IL-2) significantly extended overall survival in patients with relapsed/refractory neuroblastoma, compared to patients who did not receive immunotherapy (HR = 0.52 and 0.60 versus different historical controls) [17].